Levetiracetam or Pregabalin in Treating Seizures in Patients Undergoing Chemotherapy and/or Radiation Therapy For Primary Brain Tumors - Full Text View

Purpose

RATIONALE: Levetiracetam and pregabalin are drugs that treat seizures. It is not yet known which drug is more effective in treating seizures caused by primary brain tumors.

PURPOSE: This randomized phase II trial is studying the side effects and how well levetiracetam or pregabalin work in treating seizures in patients undergoing chemotherapy and/or radiation therapy for primary brain tumors.

Condition	Intervention	Phase
Brain and Central Nervous System Tumors Seizure	Drug: levetiracetam Drug: pregabalin	Phase II

Genetics Home Reference related topics:

pyridoxal 5'-phosphate-dependent epilepsy

MedlinePlus related topics:

Brain Cancer Cancer Seizures

ChemIDplus related topics:

Levetiracetam Pregabalin

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Supportive Care, Randomized, Open Label

Official Title:	Levetiracetam and Pregabalin for Monotherapy in Patients With Brain Tumors and Seizures. A Phase II Randomized Study.

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:

Survival without occurrence of status epilepticus, 2 seizures with consciousness impairment, need to add a second antiepileptic drug (AED) (except transitory benzodiazepine), and need to discontinue study drug for lack of efficacy or adverse events [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

Adverse events [ Designated as safety issue: Yes ]
Anxiety [ Designated as safety issue: No ]
Need to add a second AED [ Designated as safety issue: No ]
Study drug discontinuation [ Designated as safety issue: No ]
Occurrence of consciousness-impairing seizures or status epilepticus [ Designated as safety issue: No ]
Mortality [ Designated as safety issue: Yes ]

Estimated Enrollment:	60
Study Start Date:	February 2008
Estimated Primary Completion Date:	December 2010 (Final data collection date for primary outcome measure)

Detailed Description:

OBJECTIVES:

To determine the safety and efficacy of antiepileptic drug monotherapy comprising levetiracetam or pregabalin in treating seizures in patients undergoing chemotherapy and/or radiotherapy for primary brain tumors.

OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 treatment arms.

Arm I: Patients receive levetiracetam.
Arm II: Patients receive pregabalin. Patients are followed at 2 weeks, 2 months, 6 months, and then at 1 year.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

DISEASE CHARACTERISTICS:

Diagnosis of primary brain tumor
- WHO grade II-IV disease
Undergoing chemotherapy and/or radiotherapy
No brain tumor without the potential need for chemotherapy (e.g., meningioma without anaplastic features)
Has had at least one seizure provoked by the brain tumor, justifying introduction of antiepileptic drug (AED) treatment
- No status epilepticus

PATIENT CHARACTERISTICS:

Modified Rankin score < 4 at study enrollment
Life expectancy ≥ 4 weeks
Not pregnant
Negative pregnancy test
Fertile patients must use effective contraception
No known intolerance to the study drugs
No pre-existing psychosis and/or current suicidality

PRIOR CONCURRENT THERAPY:

See Disease Characteristics
No concurrent IV AEDs other than benzodiazepines
Other concurrent AEDs, except phenobarbital, allowed provided they are discontinued within 2 weeks after study enrollment

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00629889

Locations


Switzerland
	Centre Hospitalier Universitaire Vaudois	Recruiting
	Lausanne, Switzerland, CH-1011
	Contact: Andrea O. Rossetti, MD 41-21-314-1220

Sponsors and Collaborators

Centre Hospitalier Universitaire Vaudois

Investigators


Principal Investigator:	Andrea O. Rossetti, MD	Centre Hospitalier Universitaire Vaudois

More Information

Clinical trial summary from the National Cancer Institute's PDQ® database This link exits the ClinicalTrials.gov site

Study ID Numbers:	CDR0000586523, CHUV-Neurology-CePO-LEV/PGB, EU-20807
First Received:	March 5, 2008
Last Updated:	July 23, 2008
ClinicalTrials.gov Identifier:	NCT00629889
Health Authority:	Unspecified

Keywords provided by National Cancer Institute (NCI):

seizure

adult anaplastic astrocytoma

adult diffuse astrocytoma

adult pineal gland astrocytoma

adult glioblastoma

adult gliosarcoma

adult giant cell glioblastoma

adult brain stem glioma

adult ependymoblastoma

adult medulloblastoma

adult supratentorial primitive neuroectodermal tumor (PNET)

adult ependymoma

adult anaplastic ependymoma

adult anaplastic meningioma

adult anaplastic oligodendroglioma

adult oligodendroglioma

adult pineoblastoma

adult pineocytoma

mixed gliomas

adult papillary meningioma

recurrent adult brain tumor

adult grade II meningioma

Study placed in the following topic categories:

Glioblastoma

Neuroectodermal Tumors, Primitive

Astrocytoma

Seizures

Pregabalin

Central Nervous System Diseases

Central Nervous System Neoplasms

Brain Diseases

Recurrence

Ependymoma

Signs and Symptoms

Brain Neoplasms

Neuroectodermal Tumors

Epilepsy

Medulloblastoma

Neuroepithelioma

Neurologic Manifestations

Etiracetam

Oligodendroglioma

Meningioma

Glioma

Gliosarcoma

Pinealoma

Nervous System Neoplasms

Additional relevant MeSH terms:

Nootropic Agents

Neoplasms

Neoplasms by Site

Sensory System Agents

Therapeutic Uses

Physiological Effects of Drugs

Nervous System Diseases

Peripheral Nervous System Agents

Analgesics

Central Nervous System Agents

Pharmacologic Actions

Anticonvulsants

ClinicalTrials.gov processed this record on September 05, 2008

Sponsored by:	Centre Hospitalier Universitaire Vaudois
Information provided by:	National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:	NCT00629889